Connect with us

Hi, what are you looking for?

Stock

Boyu, Sinopharm among bidders shortlisted for Mundipharma China: sources

Stock Markets18 minutes ago (Jun 08, 2021 03:55AM ET)

(C) Reuters. FILE PHOTO: Signage of Sinopharm is seen at the 2020 China International Fair for Trade in Services (CIFTIS), following the COVID-19 outbreak, in Beijing, China September 5, 2020. REUTERS/Tingshu Wang

By Kane Wu

HONG KONG (Reuters) – Drugmaker Mundipharma has included Boyu Capital and state-owned Sinopharm on a shortlist of bidders for its Chinese business, two people familiar with the situation said.

Chinese buyout firms CITIC Capital and CPE are also on the shortlist for Mundipharma’s China unit, which sources have said could fetch more than $1 billion.

Mundipharma, which is owned by the billionaire American Sackler family, has chosen about half of around 20 initial possible buyers, including private equity firms and strategic players, to proceed to the next round, one of the people said.

Bids for the second round are non-binding and are due in July, the sources, who declined to be identified as the information is confidential, told Reuters.

A third person close to the situation said remaining bidders also included global and regional private equity firms.

Mundipharma and CPE declined to comment.

A spokesperson for Sinopharm said it could not comment as it did not have any relevant information on the transaction.

Boyu and CITIC Capital did not respond to Reuters queries.

Mundipharma, which is based in Cambridge, Britain, says it has a presence in 120 countries and $2 billion in global sales from drugs for pain management and supportive care, diabetes, oncology and respiratory diseases, among others.

Mundipharma launched in China, where its business now has more than 1,500 employees, in 1993 with a high-profile ceremony at the Great Hall of the People on Tiananmen Square.

Its Beijing factory is the biggest maker of narcotic and psychoactive drugs in the country, its website says, with the painkiller OxyContin one of the Chinese unit’s core products.

Deutsche Bank (DE:DBKGn) is advising Mundipharma on the sale, Reuters has previously reported. The German bank declined to comment.

Boyu, Sinopharm among bidders shortlisted for Mundipharma China: sources

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Uncategorized

Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt.

Uncategorized

Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione.

Uncategorized

Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum.

Uncategorized

Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora.

Disclaimer: Buzzclever.com it's managers and its employees (collectively "The Company") do not make any guarantee or warranty about what is advertised or above. Information provided by this website is for research purposes only and should not be considered as personalized financial or health advice. Copyright © 2021 Buzz Clever. All Rights Reserved